Surovatamig clinical trials
Also written AZD0486 and TNB-486.
How each study uses surovatamig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the surovatamig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2025 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 1
AstraZeneca (10) · Australasian Leukaemia and Lymphoma Group (1)
Studies
Open first, then newest update. How each study uses surovatamig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Not yet recruitingPhase 3AstraZenecaNCT07911553Written as Surovatamig
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingPhase 1/2AstraZenecaNCT06564038Written as Surovatamig
- Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsRecruitingPhase 1AstraZenecaNCT07201558Written as Surovatamig
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsRecruitingPhase 3AstraZenecaNCT06549595Written as Surovatamig
- A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney DiseaseRecruitingPhase 2AstraZenecaNCT07571746Written as Surovatamig
- Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLRecruitingPhase 2AstraZenecaNCT06526793Written as Surovatamig
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaRecruitingPhase 1/2AstraZenecaNCT06137118Written as Surovatamig
- AZD0486 1L Therapy for Elderly or Unfit Participants With LBCLRecruitingPhase 3AstraZenecaNCT07215585Written as AZD0486
- Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)RecruitingPhase 3AstraZenecaNCT07509151Written as Surovatamig
- A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular LymphomaNot yet recruitingPhase 3Australasian Leukaemia and Lymphoma GroupNCT07736950Written as Surovatamig
- A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1AstraZenecaNCT04594642Written as AZD0486 IV
Given beside what is tested · 1 — surovatamig is usual care or a partner of the new treatment
Codes
What other systems call surovatamig · ClinicalTrials.gg INT014716
- UNII (FDA) 3QW12I37H1SUROVATAMIGOne source FDA
- NCI Thesaurus C178577SurovatamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3QW12I37H1 | SUROVATAMIG | One source FDA |
| NCI Thesaurus | C178577 | Surovatamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.